The short version of Dihexa fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-14. Anything still debated is marked as such rather than presented as settled.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Sensory neurons (afferent): Relay sensory information in the form of an action potential (nerve impulse) from the PNS to the CNS Motor neurons (efferent): Relay an action potential out of the CNS to the proper effector (muscles, glands) Interneurons: Cells that form connections between neurons and whose processes are limited to a single local area in the brain or spinal cord Structural classification:
specific heat capacity (cp) Also massic heat capacity. The heat capacity of a sample of a substance divided by the mass of the sample. Informally, it is the amount of heat that must be added to one unit of mass of the substance in order to cause an increase of one unit in temperature. The SI unit of specific heat capacity is joule per kelvin per kilogram (J/K/kg). Specific heat capacity often varies with temperature and with each state of matter.
== Spectroscopy == Both the fluorescence excitation and emission spectrums of wild-type EosFP are shifted ~65 nm to the right upon excitation toward the red end of the spectrum. This spectral change is caused by an extension of the chromophore accompanied by a break in the peptide backbone between Phe-61 and His-62 in an irreversible mechanism. The presence of a crisp isosbestic point at 432 nm also suggests an interconversion between two species. An absorption peak at 280 nm is visible due to aromatic amino acids which transfer their excitation energy to the green chromophore. The quantum yield of the green-emitting form of Eos is 0.7. In the red shifted species, there are pronounced vibronic sidebands separate from the main peak at 533 nm and 629 nm in the excitation spectrum and emission spectrum respectively. There is another peak in the red excitation spectrum at 502 nm likely due to FRET excitation of the red fluorophore. The quantum yield of the red-emitting form is 0.55. EosFPs variants show almost no difference in spectroscopic properties, therefore, it is likely that the structural modifications which arise from separation of interfaces have little to no effect on the structure of the fluorophore-binding site.
Sources: en.wikipedia.org
== Further reading == Jung, Hans Joachim (2000). Panzer Soldiers for "God, Honor and Fatherland": The History of Panzerregiment Grossdeutschland. Winnipeg, Canada: J. J. Fedorowicz. ISBN 0-921991-51-7. Herbst, Jurgen (2002). Requiem for a German Past: A Boyhood among the Nazis. Madison, Wisconsin: University of Wisconsin Press. ISBN 978-0-299-16414-0. de Lannoy, François; Perrigault, Jean-Claude (1998). La Grossdeutschland: du régiment au Panzerkorps, 1939–1945 [Grossdeutschland: From Regiment to Panzer Corps 1939–1945] (in French). Bayeux, France: Heimdal. ISBN 2-84048-110-3. Lucas, James (1978). Germany's Elite Panzer Force: Grossdeutschland. London: Macdonald and Jane's. ISBN 0-35401-165-0. McGuirl, Thomas; Spezzano, Remy (1997). God, Honor, Fatherland: A Photo History of Panzergrenadier Division Grossdeutschland on the Eastern Front 1942 - 1944. Connecticut: Southbury. ISBN 0-9657584-0-0. Novotny, Alfred (2002). The Good Soldier: From Austrian Social Democracy to Communist Captivity with a Soldier of Panzer-Grenadier Division Grossdeutschland. Bedford, Pennsylvania: Aberjona Press. ISBN 0-966638-99-9. Quarrie, Bruce (1977). Panzer-Grenadier Division Grossdeutschland. London: Osprey Publishing Group. ISBN 0-85045-055-1.
== In biology == The best-studied 2-Carboxy-D-arabinitol-1-phosphate phosphatase is the enzyme that inactivates the RuBisCO inhibitor 2-carboxy-D-arabinitol-1-phosphate (CA1P). When light levels are high, the inactivation occurs after CA1P has been released from RuBisCO by RuBisCO activase. As CA1P is present in many but not all plants, CA1P-mediated regulation of RuBisCO is not universal for all photosynthetic life. Amino acid sequences of the CA1Pase enzymes from wheat, French bean, tobacco, and Arabidopsis thaliana reveal that the enzymes contain 2 different domains, indicating that it is a multifunctional enzyme. CA1Pase enzyme activity varies between different species due to their regulation by different redox-active compounds, such as glutathione. However, it is yet to be determined whether this process occurs in vivo. Wheat CA1Pase heterologously expressed in E. coli is also able to dephosphorylate the RuBisCO inhibitor D-glycero-2,3-diulose-1,5-bisphosphate.
The basic equation of radiometric dating requires that neither the parent nuclide nor the daughter product can enter or leave the material after its formation. The possible confounding effects of contamination of parent and daughter isotopes have to be considered, as do the effects of any loss or gain of such isotopes since the sample was created. It is therefore essential to have as much information as possible about the material being dated and to check for possible signs of alteration. Precision is enhanced if measurements are taken on multiple samples from different locations of the rock body. Alternatively, if several different minerals can be dated from the same sample and are assumed to be formed by the same event and were in equilibrium with the reservoir when they formed, they should form an isochron. This can reduce the problem of contamination. In uranium–lead dating, the concordia diagram is used which also decreases the problem of nuclide loss. Finally, correlation between different isotopic dating methods may be required to confirm the age of a sample. For example, the age of the Amitsoq gneisses from western Greenland was determined to be 3.60 ± 0.05 Ga (billion years ago) using uranium–lead dating and 3.56 ± 0.10 Ga (billion years ago) using lead–lead dating, results that are consistent with each other.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.